Apr 15, 2026 5:30pm EDT Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation
Feb 11, 2026 5:30pm EST Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Nov 17, 2025 8:30am EST Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Nov 12, 2025 6:06pm EST Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Sep 25, 2025 5:30pm EDT Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Aug 12, 2025 5:30pm EDT Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection
